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9 Abstract
10 HERVH is one of the most successful endogenous retrovirus in the human genome. Relative 
11 to other endogenous retroviruses, slower degradation of HERVH internal sequences indicates 
12 their potential relevance for the host. HERVH is transcriptionally active during human 
13 preimplantation embryogenesis. In this review, we focus on the role of HERVH in regulating 
14 human pluripotency. The HERVH-mediated pluripotency network has been evolved recently 
15 in primates. Nevertheless, it became an essential feature of human pluripotency. We discuss 
16 how HERVH modulates the human pluripotency network by providing alternative 
17 transcription factor binding sites, functioning as a long-range enhancer, and as being a major 
18 source for pluripotency specific long non-coding RNAs and chimeric transcripts.
19
20 Highlights
21 HERVH expression marks human pluripotent stem cells
22 HERVH provides binding site for key pluripotency transcription factors
23 HERVH gives rise to pluripotency specific lncRNAs, lincRNAs and chimeric transcripts
24 HERVH is needed for acquisition and maintenance of pluripotency
25 HERVH is required for self-renewal and inhibits differentiation
26
27 Introduction
228 Retroviruses have invaded the genome of human ancestors in several waves [1,2]. If a 
29 retrovirus successfully integrates in the germline, it can go through an endogenization 
30 process. The endogenization process enables their vertical transmission from parent to 
31 progeny via germline transmission [3]. The endogenized retroviruses (ERVs) eventually lose 
32 their ability to infect and leave the cells [3], and follow the life cycle of transposable elements 
33 (TEs) [4,5]. Following an active period of transposition and amplification, ERVs get 
34 inactivated transpositionally, and subjected to a degradation process [6]. As viral fossils, ERV 
35 sequences were long considered to have no functional relevance in the human genome and 
36 indeed many are probably functionless degrading fossils. Intriguingly, ERV-derived 
37 sequences can, however, be occasionally co-opted by the host for various cellular processes. 
38 As a classical example, ERV-derived fusogenic syncytin genes have important function in 
39 placenta development and embryo implantation in mammals [7,8]. Located in the vicinity of 
40 certain immune genes, ERV-derived sequences function as interferon-γ inducible enhancers 
41 and regulate the transcription of immune genes  [9], underlying their involvement in fine-
42 tuning the innate immune responses. Several ERV families show transcriptional activity 
43 during early embryogenesis [10,11]. Recently, two ERV families, HERVK and HERVH, have 
44 been implicated in a domestication process, being incorporated into the host defense against 
45 exogenous viral infection [11] and the regulatory network of pluripotency, respectively 
46 [10,12,13].
47
48 Endogenous retroviruses as transposable elements 
49 TEs are almost certainly present in all species, with significant contributions to genome 
50 structure (in humans, for example, it is 45-65%) [14,15]. The most common TEs in 
51 mammalian genomes are the retrotransposons that use a reverse transcription step during 
52 transposition [16]. They are classified, based on the presence of a long terminal repeat (LTR), 
53 into non-LTR and LTR retrotransposons. [17]. ERVs belong to the latter. Transposition of an 
54 intact ERV is initiated by transcriptional activation. The mRNA is then translated into gag 
55 and pol polyproteins. The pol open reading frame includes a protease, a reverse transcriptase, 
56 an RnaseH, and an integrase coding sequence. The gag protein encapsulates these viral 
57 proteins and the ERV RNA, which is reverse-transcribed into DNA and is integrated into a 
58 target genomic location [4,5,17]. Although transposing ERVs can pose a great mutagenic 
59 potential [18,19], there are no confirmed transpositionally active ERVs in the human genome 
60 [20-22]. Nevertheless, one of the youngest ERV families, HERVK, has been active recently 
361 enough to be polymorphic loci in the human genome [23,24]. By contrast, a few, 
62 phylogenetically younger (< 7 million years old) subfamilies of the non-LTR 
63 retrotransposons, including Line1 (L1), SVA and Alu elements are still actively jumping [22].
64
65 HERVH invaded primates genomes in multiple waves
66 Today, ERV-related sequences make up about 8% of the human genome [15,25]. These 
67 sequences belong to different human ERV (HERV) families which are classified by their 
68 tRNA primer binding sites (e.g lysine for HERVK, histidine for HERVH etc.) [26]. HERVH 
69 integrated into the genome of human ancestors at the time of divergence of Old and New 
70 World monkeys, 30-40 million years ago (MYA) [27,28], with an expansion at about 25 
71 MYA [27]. The expansion of HERVH coincided with the loss of the env gene [29]. This 
72 process resulted in high HERVH copy numbers in the Old World monkeys (approximately 
73 900 [30]) compared with only a few (25-50 copies) in New World monkeys [28]. 
74 Interestingly, another wave of invasion of HERVH retrovirus [31] has occurred at the 
75 divergence of hominoids between 10 and 17 million years ago, resulting in about 100 
76 additional copies [27]. HERVH as retrovirus has been inactivated around 10 MYA [32].
77
78 HERVH is the most abundant ERV in the human genome
79 The first HERVH copy, a deleted version of the full-length elements, was identified from the 
80 human genome in 1984 [33]. It was a 5-6 kb repetitive sequence that consisted of the 415 bp 
81 LTRs, flanking the internal sequence and a histidine tRNA primer binding site that was 
82 located directly after the 5’LTR. The regulatory LTR sequences which flank the HERVH 
83 internal sequence (HERVH-int) are characteristic to HERVH elements and the HERVH 
84 related LTR subtypes are LTR7, LTR7A, LTR7B, LTR7C and LTR7Y [34], representing 
85 different evolutionary age. Other than their regulatory LTRs, HERVHs, are further 
86 characterized based on their structure into complete, slimmed down, substituted and solo LTR 
87 elements [16]. 
88 The human genome contains around 50-100 copies of the almost intact forms of HERVH with 
89 a full-length size of 8.7 kb [35-37]. A few HERVH copies have an env open reading frame 
90 which, however, has not been found to produce a protein [38]. Although the almost intact 
91 HERVH copies have the full repertoire of retroviral genes, these carry several mutations or 
492 deletions and are not replication competent [18,35,37]. The vast majority of the HERVH 
93 integrations in the human genome originate from a common 5.8 kb form with a structure of 
94 5’LTR-gag-pol-3’LTR [39] (Figure 1) that carries large deletions in its pol coding region [28] 
95 and lacks the env coding region [28,35-37]. The integrity of an inactive ERV is typically not 
96 protected, and their sequences are exposed to various degradation processes such as 
97 homologous recombination that generates solitary LTR copies, and various insertions and 
98 deletions (indels), resulting in fragmentation and even in complete ‘stochastic loss’. During 
99 the degradation process, the active full-length elements, operating as autonomous 
100 retrotransposition machineries, might mobilize the more common and partially deleted non-
101 autonomous forms of ERVs [5,28].
102 What is noteworthy about HERVH compared to other ERV families is the unusually high 
103 number of full-length and partially deleted insertions relative to solitary LTRs [40,41], 
104 suggesting that the degradation of HERVH copies occur at a much slower rate compared to 
105 other ERVs (Figure 2) [40]. With 1060 copies flanked by LTRs and another 1270 copies of 
106 solitary LTR sequences per haploid genome [29], HERVH is the HERV family with the 
107 highest copy number in the human genome [27,33]. Lack of the env coding region, as part of 
108 the endogenization process, has been associated with the ability to more effectively amplify in 
109 copy number [42], of this ERV within the human genome. The maintenance of HERVH full 
110 length or partially deleted forms in the human genome gave rise to the hypothesis that some 
111 HERVH sequences might have gained functional relevance for the host [40]. 
112
113  HERVH gets transcriptionally activated during human preimplantation embryogenesis 
114 following an exceptional pattern
115 Mammalian preimplantation embryogenesis passes the following stages: the fertilized oocyte 
116 forms a zygote, which develops into a 2-cell, 4-cell and 8-cell embryo, followed by the 
117 morula and then the blastocyst. During these stages the totipotent cells of the zygote become 
118 pluripotent within the epiblast of the blastocyst [43]. The pluripotent epiblast can still give 
119 rise to ectoderm, mesoderm and endoderm, but no longer to extraembryonic tissues. The 
120 process of preimplantation embryogenesis involves rapid, dynamic, and well-orchestrated 
121 changes in the epigenome of the embryo. The global epigenetic changes gradually deactivate 
122 the transcription of various TE families (including both transpositionally competent and 
123 inactive) in a well-defined temporal order [10]. In fact, the transcriptome of TEs differs so 
5124 dramatically between the stages of embryogenesis, that the cell status can be identified solely 
125 based on their expression pattern (Figures 3 and 4) [10,11]. For the sake of genome stability, 
126 repression of actively transposing retrotransposons by the host is selectively favored during 
127 embryogenesis [44]. Indeed, the host has evolved several layers of regulatory mechanisms to 
128 control TE activities. Transcription from a TE locus is epigenetically regulated by DNA 
129 methylation and histone modification. The KRAB-ZN finger proteins can specifically 
130 recognize TE families and recruit the TRIM28/KAP1 repression complex and induce 
131 heterochromatin formation [45]. At the portranscriptional level, TEs can be also controlled by 
132 small RNA-mediated silencing or by APOBEC-mediated gene editing [46-49]. Although 
133 these regulatory mechanisms were established during the ‘arms race’ between TEs and the 
134 host [44], several of them are still functional (e.g. control the transcription). 
135 Initial stages of embryonic development are governed by maternal effects [50], and  
136 embryonic genome activation (EGA) in the human embryo occurs later than in mice (2 cell), 
137 and only between the 4- and 8-cell stages of development (Figure 3A and 4) [51]. Notably, a 
138 massive activation of TEs in both species occurs at the switch from maternal to embryonic 
139 genome activation [10]. In human, DNA transposon-derived transcripts are relatively 
140 abundant in zygotes and 2-cells stage, but their levels, together with other phylogenetically 
141 Old (> 7 MY) TEs, gradually decline as development proceeds (Figure 3B). This might reflect 
142 decay of remnant RNAs expressed in oocytes. In human, the transcriptional activation of the 
143 Young (< 7 MY) elements, including L1 (L1_Hs) and SVA (SVA_D, E and F), capable of 
144 retrotransposition [52] is substantial from 8-cell stage, peaking at morula with a contrasting 
145 dynamic to DNMT3A and 3B, but declining in the blastocyst (Figure 3C). “Old” LTR7-
146 HERVH peaking at the blastocyst [10,11] is the one exception to the Old/Young difference, 
147 and curiously opposing the expression pattern of Young TEs, including the mutagenic SVA or 
148 the human specific HERVK_Hs elements (Figure 3C). 
149 Contrary to other TEs, transcriptional activation of HERVH (with various intensity) occurs 
150 throughout early human development. Based on the LTR type, the expression of LTR7- and 
151 LTR7Y-driven HERVH peaks at the blastocyst [10,11], LTR7B-driven HERVH is 
152 transcribed at the 8-cell stage, while HERVH associated LTR7 sequence with a certain 38 bp 
153 deletion is activated even before the 8-cell stage of human preimplantation embryogenesis 
154 (Figure 4) [10]. Thus, HERVH, driven by distinct LTR variants, is expressed during the entire 
155 human preimplantation embryogenesis [10].
156
6157 HERVH expression in human pluripotent stem cells
158 In vitro models of human pluripotency maintenance and differentiation are pluripotent stem 
159 cells, including human embryonic stem cells (hESCs) [53] and induced pluripotent stem cells 
160 (hiPSCs) [54]. While hESC cultures are established from the pluripotent blastocysts, iPSCs 
161 are reprogrammed somatic cells that have regained a pluripotent state. Both, hESCs and 
162 hiPSCs are enriched for LTR7-driven HERVH and associated transcripts (Figure 5A and B) 
163 [10,12,13,55], indicating that HERVH-derived transcripts are hallmarks of human pluripotent 
164 stem cells (hPSCs). HERVH transcripts are highly abundant and account for 2% of total RNA 
165 in hPSCs [39] and are concentrated in the nucleus [56]. The transcription of HERVH is 
166 supported by open chromatin [57,58], characterized by markers for transcriptionally active 
167 promoters like H3K4me1/2/3, H3K9ac, H3K27ac, H3K36me3 and H3K79me2 [12,39,55,59]. 
168 By contrast, repressive chromatin marks of H3K27me3 and H3K9me3 at the transcriptionally 
169 active HERVH loci are rare [12]. Thus, LTR7 has an active function as promoter and 
170 enhancer in hESCs [10,58].
171
172 HERVH provides a platform to key pluripotency transcription factors 
173 How is it that HERVH is transcriptionally active in pluripotent stem cells? In the human 
174 genome, one fourth of the all the binding sites for transcription factors modulating 
175 pluripotency are provided by TEs [60]. Active HERVH copies have binding sites for four key 
176 transcription factors driving pluripotency, such as OCT4, SOX2, LBP9 (TFCP2L1) and 
177 NANOG [12,61-63]. Specifically, NANOG has been shown to bind the 5’LTR of HERVH, 
178 while OCT4 and SOX2 have binding sites in the HERVH internal sequence towards its 5’ end 
179 [39]. 
180 Functioning as a platform for alternative transcription factor binding sites and as long-range 
181 enhancers, LTR7/HERVH is expected to affect the transcriptional regulatory network of 
182 pluripotency (Figure 6A). In fact, HERVH is indispensable for pluripotency maintenance, as 
183 knocking down of HERVH in hPSCs results in loss of pluripotency [12,56,64]. Curiously, the 
184 global knockdown effect of HERVH and LBP9 are correlated, suggesting that the functions of 
185 LBP9 binding to HERVH and modulating pluripotency might have evolved together [12]. 
186 Besides regulating pluripotency, the observed correlation argues for an additional function of 
187 LBP9 in retroviral control present only in primates (hence the name LTR-binding protein 9).
7188
189 HERVH produces pluripotency-specific ncRNAs
190 How might HERVH impact on pluripotency? Noncoding RNAs (ncRNAs) have been 
191 frequently found to be involved in regulating developmental processes including pluripotency 
192 and differentiation [65-67]. While TEs contribute very little to protein coding sequences [68], 
193 they give rise to numerous ncRNAs, including long non-coding RNAs (lncRNAs), long 
194 intergenic non-coding RNAs (lincRNAs), microRNAs, etc [69,70]. Intriguingly, TEs are 
195 integral to 83% of lincRNAs [68] and thus likely shaped their evolution. Once upregulated, 
196 HERVH affects the expression of genes within a 40 kb window [55]. In hPSCs, HERVH 
197 serves as a major source of alternative transcripts, regulating pluripotency [58,60]. These 
198 HERVH-derived transcripts were recruited in a primate [12,30] or even human-specific 
199 manner [30]. Transcriptionally active HERVHs are driving the production of numerous 
200 lncRNAs and lincRNAs [12,69-72]. LTR7/HERVH sequences alone account for more than 
201 43% of hESC-specific lncRNA promoters [13] and give rise to over a hundred (127) 
202 lincRNAs which are robustly and specifically transcribed in hPSCs [68,72].
203 Transcription of HERVH derived lincRNAs requires prior binding of SP1, OCT4 or NANOG 
204 to the 5’LTR of HERVH [56,68]. Curiously, HERVH-lncRNAs share a conserved core 
205 domain [12], which is capable of recruiting RNA-binding proteins, pluripotency factors and 
206 histone modifiers [12,67]. As a scaffold, HERVH-derived nuclear lncRNA interacts with 
207 pluripotency factors (e.g. OCT4) and transcriptional co-activators (e.g. p300, mediator 
208 subunits MED6 and MED12) [66,67]. This scaffold acts as a feedback regulator, modulates 
209 LTR7 enhancer function and the expression of neighboring genes that are essential for hPSCs 
210 identity (Figure 6B) [56]. An interesting example of HERVH-lincRNA is the linc-Regulator 
211 of Reprogramming (linc-RoR) that supports pluripotency by functioning as a miRNA sponge. 
212 Linc-RoR shares miRNA response elements with core pluripotency transcription factors 
213 OCT4, SOX2 and NANOG, thus protecting them from miRNA-mediated decay (Figure 6C) 
214 [73].
215
216 HERVH produces chimeric transcripts between cellular and viral sequences
217 Another means by which HERVH regulates pluripotency maintenance in hPSCs is via  the 
218 generation of various chimeric transcripts thereby combining cellular and viral sequences. 
8219 HERVH contains a conserved splice donor site that can connect the retroviral element with 
220 splice acceptor sites of cellular protein-coding genes (Figure 1) [10]. With a transcriptional 
221 start site (TSS) between the 5’LTR and HERVH sequence, these chimeric transcripts often 
222 lack their 5’ exon(s) of the canonical version, while part of HERVH can be exonized. 
223 Examples of HERVH-enforced chimeras include SCGB3A2, RPL39L, RP11-69I8.2NCR1, 
224 OC90 and CALB-KLKB1 [12]. We assume that the function of novel HERVH-enforced 
225 chimeras may be related to the original gene, but modified. However, in certain cases the 
226 LTR7/HERVH-enforced chimeric gene model is so robustly altered that it is not even 
227 possible to predict its new function. 
228 An interesting example of a HERVH enforced novel transcript, part HERVH, part host DNA, 
229 is ESRG that has a putative open reading frame (or frames) only in humans [12,74]. ESRG is 
230 expressed in hPSCs [12,74,75], and has been shown to promote the reprogramming process 
231 [12]. A knockdown of ESRG hampers the self-renewal potential and pluripotency of hPSCs 
232 [12]. The case of the ESRG gene is extreme as it consists almost entirely of repetitive 
233 sequences [12]. The non-HERVH sequence recruited is intronic DNA from the host gene 
234 within which ESRG resides. The ability of HERVH to generate a great degree of diversity via 
235 its heterogeneous transcripts can in part explain why selection may have favoured the 
236 preservation of some HERVH-associated transcripts. With such a diversity it is more likely 
237 that a few will evolve new functions in the cells in which they are easily expressed.
238
239 HERVH promotes somatic cell reprogramming 
240 Human somatic cells can be reprogrammed to become pluripotent via different routes. The 
241 classical way is the forced expression of pluripotency factors OCT4, SOX2, KLF4 and c-
242 MYC (referred to as the OSKM factors) [12,54]. Alternatively, hiPSCs can be generated by 
243 ectopic expression of combinations of other pluripotency-specific transcription factors (e.g. 
244 NANOG, LIN28), small molecules (e.g. VPA, BIX01294), and/or ectopic expression of 
245 microRNAs (e.g. miR302/367) [76,77]. hiPSC generation is a slow, stochastic process that 
246 can be accelerated by manipulating cell division rate through inhibition of the p53/p21 
247 pathway [76] and ectopic expression of connexin 45 [78] or LIN28 [76]. 
248  By providing specific binding sites for pluripotency factors LTR7/HERVH is good source 
249 material to evolve functions that influence the process of somatic cell reprogramming 
9250 [12,60,71,72]. Indeed, exogenous NANOG can activate HERVH transcription in fibroblasts 
251 and promote the acquisition of pluripotency in somatic cells [71]. Furthermore, the ectopic 
252 expression of OCT4 would only increase reprogramming efficiency when certain HERVH 
253 transcripts are present [71]. Thus, besides serving as a binding platform for pluripotency 
254 specific transcription factors, HERVH driven transcripts facilitate the hiPSC generation. 
255 Indeed, certain LTR7/HERVH products (e.g ESRG, linc-RoR), implicated in promoting 
256 reprogramming are expressed during the process (Figure 5B) [12,72]. Only when the 
257 reprogramming is completed and cells have acquired the pluripotent state do the levels of 
258 HERVH and its flanking LTR7 drop to those observed in hESCs [12]. In line with this, linc-
259 RoR, thought to be a direct target of pluripotency factors, is silenced when cells adapt to a 
260 differentiated phenotype [56,67]. However, LTR7/HERVH expression stays high in some 
261 hiPSC lines vs hESCs [55,56,64,67]. Failure to suppress LTR7 and pluripotency transcription 
262 factor KLF4 after reprogramming is complete leads to a differentiation defective phenotype 
263 [64]. In these cells, KLF4 binding is thought to antagonize TRIM28/KRAB-associated protein 
264 1 (KAP-1) binding to LTR7, thereby preventing HERVH suppression [44,64].
265 hiPSCs, in comparison with hESCs, are more prone to genomic and epigenetic aberrations 
266 [79-82]. These include random point-mutations, duplications and deletions in protein coding 
267 and non-coding regions [82].The epigenetic turbulence during the reprogramming process 
268 also activates TEs in a characteristic pattern. While young TEs, such as the HERVK_Hs is 
269 preferentially active during the intermediate stage of the reprogramming process, LTR7-
270 driven HERVH expression increases and stays high in cultured hiPSCs [12,20], where 
271 HERVK_HS expression is simply a read-through event [12]. Reprogramming has been 
272 reported to activate the young mutagenic elements (e.g. L1 and SVA). Low activity of the L1 
273 and SVA has been also reported to occur during hPSCs culturing in both hESC and hiPSC 
274 cultures [83]. 
275 Collectively, in addition to the role in supporting self-renewal and inhibiting differentiation, 
276 LTR7/HERVH plays a role in pluripotency acquisition, and perhaps in stabilization of the 
277 pluripotent state, underlining the various cellular functions of HERVH that might affect 
278 pluripotency.
279
280 HERVH as a marker of naïve-like pluripotency
10
281 Ground-state or naïve pluripotency is an ability of the pluripotent blastocyst for unbiased 
282 differentiation. In vitro hPSC cultures consist of a heterogeneous cell population [53] with 
283 only around 4% naïve-like cells exhibiting naive-like pluripotency [12]. Importantly, these 
284 naïve-like cells can be identified based on elevated LTR7/HERVH [12] expression compared 
285 to primed hESCs. Higher expression levels of HERVH in naïve-like hPSCs have been 
286 associated with a subset of HERVH possessing a binding site for the pluripotency 
287 transcription factor LBP9 [12,84]. This initiates transcription of specific lncRNAs and 
288 chimeric transcripts as a part of the primate-specific pluripotency network [12]. Others have 
289 reported LTR7Y/HERVH [10], HERVK or SVA as being a more precise marker for naïve-
290 like hPSCs [11,85]. This discrepancy could be explained with the existence of various naïve-
291 like cell lines. Which naïve-like cell line mimics real developmental conditions most 
292 precisely, remains currently a matter of debate. Importantly, however, SVA is potentially 
293 mutagenic, and in contrast to HERVH, to date there is no evidence of HERVK function in 
294 pluripotency.
295
296 Conclusions
297 Here, we have reviewed the recent literature on HERVH in regulating human pluripotency. 
298 The HERVH-mediated circuitry, modulating pluripotency has been evolved recently in 
299 primates. The conserved function of HERVH expressing ncRNA, estimated to arose before 
300 the divergence of gorilla [86]. Nevertheless, the HERVH-derived regulatory network has been 
301 incorporated, and appears to be an essential feature of human pluripotency. In what way 
302 pluripotency is specific to us humans, still needs to be deciphered. HERVH provides binding 
303 sites for pluripotency transcription factors, functions as a long-range enhancer and serves as a 
304 major source for ncRNAs and chimeric transcripts in hPSCs. A few of the many HERVH 
305 enforced pluripotent stem cell specific transcripts have been already characterized to have 
306 functionality. However, as the domestication process of HERVH is relatively young, it 
307 remains to be also established what proportion of the HERVH associated transcripts is 
308 functional. The diverse mechanisms, by which HERVH participates in modulating 
309 pluripotency are only starting to be elucidated. Finally, besides regulating pluripotency, 
310 HERVH might have been co-opted to other functions in other stages of the preimplantation 
311 embryogenesis.
312
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566 Figure legends
567 Figure 1. Structure of the most common HERVH sequence in the human genome. Internal 
568 sequence of HERVH consists of viral genes gag and pol carrying mutations and deletions (not 
569 shown) and is flanked by regulatory long-terminal repeats (LTRs) which in case of HERVH 
570 are classified as type 7 LTR. Near the 5’LTR7 is the histidine tRNA binding site (PBSHis), 
571 hence the name HERVH, and near the 3’LTR7 is the polypurine tail (PPT). SD and SA 
572 indicate splice donor and splice acceptor sites, respectively.
573 Figure 2. Predicted deletion dynamics of full-length ERVs in the next 25 million years. 
574 HERVHs would degrade more slowly compared to three other HERVs, including HERVKs 
575 (estimates on deletion dynamics of full length elements: under a Weibull model, thick 
576 black/thin grey lines; under an exponential model, black dotted lines). Adapted from [40]..
577 Figure 3. Expression dynamic of selected enzymes affecting genomic DNA methylation 
578 during preimplantation embryogenesis in human vs mouse (data minding of single cell 
579 transcriptome data. Lines on the plot are connecting medians of single cell expression levels 
580 (log2 TPM) from the depicted stages of development (data mining of [87]). ‘Early’ includes 
581 oocytes, zygote, 2-cell, 4-cell stages in human, while zygote, early 2-cell, late 2-cell, 4-cell in 
582 mouse. ‘Mid’ represents 8-cell, 16-cell/morula stages, and ‘Late’ denotes blastocysts in both 
583 human and mouse. Lines are smoothed by spline function (spar=45) (A). Expressional 
584 dynamics of Old (> 7MY) and Young (< 7MY) TEs during human preimplantation stages 
585 (B). Expressional dynamics of Young (< 7MY) TEs during human pre-implantation-stages. 
586 TEs marked with * were demonstrated to retrotranspose in human [52]. Note that the 
587 youngest LTR7, LTR7Y is (> 7MY) is included in the analysis (C). 
588 Figure 4. HERVH expression driven by LTR7 (LTR7, LTR7 with 38 base pair deletion, 
589 LTR7B and LTR7Y) during early human embryogenesis. Untypical to other retroelements, 
590 LTR7/HERVH expression peaks in human blastocyst. HERVH elements driven by LTR7 
591 carrying a 38 base pair deletion is expressed in four cells stage, LTR7B in 8 cells/morula. 
592 HERVH driven by the youngest LTR7Y is expressed from 8 cells to blastocyst.
593 Figure 5. HERVH expression driven by LTR7 in models of pluripotency: human embryonic 
594 stem cells (A) and induced pluripotent stem cells (iPSCs) (B). Harvested from the pluripotent 
595 epiblast of the blastocyst, hESCs are enriched for HERVH driven by LTR7/7Y. In the 
596 heterogeneous population of hPSCs, naïve-like hPSCs can be identified by LTR7/7Y 
597 expression (A). Certain HERVH driven products (ESRG, linc-RoR) promote the acquisition 
18
598 of pluripotency during somatic cell reprogramming and increases the efficiency of iPSC 
599 generation (B).
600 Figure 6. LTR7/HERVH modulates the human regulator network of pluripotency in various 
601 ways. HERVH provides binding sites for pluripotency associated transcription factors 
602 (triangles), such as NANOG, LBP9, OCT4 and KLF4. Besides transcribing HERVH-derived 
603 products, HERVH also acts as a long-range enhancer, modulating the expression of 
604 pluripotency genes (e.g. Gene B) (A). HERVH is a source for pluripotency-specific chimeric 
605 transcripts (example ESRG which has a putative open reading frame only in humans) as well 
606 as long non-coding RNAs (lncRNAs; example linc-RoR). HERVH derived linc-RoR 
607 functions as a microRNA sponge and protects pluripotency associated transcription factors 
608 from microRNA-mediated suppression (B). Certain HERVH derived transcripts act as a 
609 scaffold, recruiting transcription factors and co-activators, regulating LTR7 enhancer function 
610 and expression of certain genes (example Gene B) (C).






